On May 27, 2025, iTeos Therapeutics, Inc. announced plans to wind down its operations due to strategic reviews and the termination of its belrestotug program, with expected costs between $32.9 million to $35.8 million for severance and program-related wind down. The company anticipates completing this process by Q3 2025, subject to ongoing consultations.